m+Medelevator.RU
← Поиск публикаций
Analytical and bioanalytical chemistry · 2026

Nitrogen-doped carbon nanodots-based "off-on" fluorescent sensor for the detection of breast cancer-derived exosomes and early diagnosis.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Tang Hongchao, Chen Yiling, Shang Jiangfeng, Zhu Liquan, Xu Jingyuan, Wu Chaoshen, Zhou Yibing, Xu Wenqian, Liu Xiaozhen, Qian Da, Meng Xuli, He Chaoqi

Аннотация

Breast cancer is a leading cause of cancer death in women, requiring non-invasive early diagnostic tools. Exosomes are promising liquid biopsy biomarkers that reflect tumor-derived molecular information. Here, we developed an "off-on" fluorescent sensor using nitrogen-doped carbon nanodots (N-CNDs) for sensitive detection of breast cancer-derived exosomes. The sensor uses a magnetic bead-based aptamer complex (MBs-Apt-P1-P2) for target capture. P1 and P2 probes contain both EpCAM-recognition and Poly-T sequences. In the absence of targets, Ag+ quenches N-CNDs fluorescence. Upon target introduction, aptamers bind exosomal EpCAM, competitively releasing P1/P2 probes. After magnetic separation, the released Poly-T sequences capture Ag+ via T-Ag+-T coordination, restoring N-CNDs fluorescence. Each exosome can release two probes, providing dual signal amplification. Under optimal conditions, the sensor responded linearly to 1 × 109-4 × 1011 particles/mL with a detection limit of 35 particles/mL, showing excellent sensitivity for EpCAM-positive breast cancer exosomes. Clinical testing on 11 serum samples (6 patients, 5 healthy donors) distinguished patients with an AUC of 0.94, compared with ELISA (AUC = 0.88). This sensor offers a promising platform for breast cancer detection with high sensitivity and accuracy, warranting further validation in large-scale clinical studies.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты